SUVN 502

Drug Profile

SUVN 502

Alternative Names: M1; M1 of SUVN-502; SUVN502; SVN-502

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Suven Life Sciences
  • Class Antidementias; Antiparkinsonians; Antipsychotics; Small molecules
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders; Parkinson's disease; Schizophrenia

Highest Development Phases

  • Phase II Alzheimer's disease; Schizophrenia
  • No development reported Attention-deficit hyperactivity disorder; Cognition disorders; Parkinson's disease

Most Recent Events

  • 12 Jul 2018 Chemical structure information added
  • 22 Jun 2018 Suven Life Sciences initiates an expanded-access programme for Alzheimer's disease in USA (NCT03564964)
  • 22 Mar 2018 Suven Life Sciences has patent protection for 5-HT6 compounds in Norway, South Korea and Singapore
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top